Dopamine D3 receptors: Relevance for the drug treatment of Parkinson's disease

CNS Drugs

Volumn 12, Issue 5, 1999, Pages 391-402

  Levant, Beth ^a   Ling, Zao Dung ^b   Carvey, Paul M ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; APOMORPHINE; BROMOCRIPTINE; DOPAMINE; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LISURIDE; PERGOLIDE; PRAMIPEXOLE; RECEPTOR SUBTYPE; ROPINIROLE;

BRAIN PROTECTION; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; EDEMA; HUMAN; NEUROLOGIC DISEASE; NEUROTRANSMISSION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0032718288     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199912050-00006     Document Type: Review

References (101)

1. 1. Adler CH, Sethi KD, Hanser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393-9
2. 2. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996; 19: 234-45
3. 3. Shannon KM, Bennett JPJ, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724-8
4. 4. Tulloch IE. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology 1997; 49: S58-S62
5. 5. Sage JI, Duvoisin RC. Pergolide. In: Koller WC, Paulson GW, editors. Therapy of Parkinson's disease. New York (NY): Marcel Dekker, Inc., 1995: 249-59
6. 6. Horowski R, Obeso JA. Lisuride. In: Koller WC, Paulson GW, editors. Therapy of Parkinson's disease. New York (NY): Marcel Dekker, Inc., 1995: 219-48
7. 7. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-8
8. 8. Kebabian JW, Calne DB. Multiple receptors for dopamine.Nature 1979; 277: 93-6
9. 9. Sokoloff P, Giros B, Martres MP, et al. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146-51
10. 10. Sunahara RK, Guan HC, O'Dowd BF, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 1991; 350: 614-9
11. 11. Van Tol HH, Bunzow JR, Guan HC, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-4
12. 12. Giros B, Martres MP, Sokoloff P, et al. Clonage du gene du recepteur dopaminergique D3 humain et identification de son chromosome, [Gene cloning of human dopaminergic D3 receptor and identification of its chromosome|. C R Acad Sci III 1990; 311 (13): 501-8
13. 13. Lannfelt L, Sokoloff P, Martres MP, et al. Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992; 2: 249-56
14. 14. Piercey MF, Hoffmann WE, Smith MW, et al. Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists. Eur J Pharmacol 1996; 312: 35-44
15. 15. Piercey MF, Walker EL, Feldpausch DL, et al. High affinity binding for pramipexole, a dopamine D3 receptor ligand, in rat striatum. Neurosci Lett 1996, 219: 138-40
16. 16. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 1997; 49: 231-52
17. 17. Bowen WP, Coldwell MC, Hicks FR, et al. Ropinirole, a novel dopaminergic agent for the treatment of Parkinson's disease, with selectivity for cloned dopamine D3 receptors [abstract]. Br J Pharmacol 1993; 110 Suppl.: 93P
18. 4 receptors in functional studies using microphysiometry [abstract]. Br J Pharmacol 1996; 119 Suppl: 346P
19. 3 receptors. Eur J Pharmacol 1999;366:293-300
20. 20. Mierau J. Pramipexole: a dopamine-receptor agonist for treatment of Parkinson's disease. Clin Neuropharmacol 1995; 18 Suppl. 1: S195-S206
21. 21. Levant B, Vansell NR. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology 1997; 17: 67-71
22. 22. Dolphin AC, Scott RH, Calcium channel currents and their inhibition by (-)-baclofen in rat sensory neurones: modulation by guanine nucleotides. J Physiol (Lond) 1987; 386: 1-17
23. 23. Herroclen L, De Backer JP, Wilczak N, et al. Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res 1994; 648: 222-8
24. 24. Hall ED, Andrus PK, Oostveen JA, et al. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res 1996; 742: 80-8
25. 25. Murray AM, Ryoo HL, Gurevieh E, et al. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A 1994; 91: 11271-5
26. 26. Levant B, Bancroft GN, Selkirk CM. In vivo occupancy of D2 dopamine receptors by 7-OH-DPAT. Synapse 1996; 24: 60-4
27. 27. Lahti RA, Roberts RC, Tamminga CA. D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport 1995; 6: 2505-12
28. 28. Bouthenet ML, Souil E., Martres MP, et al. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res 1991; 564: 203-19
29. 29. Landwehrmeyer B, Mengod O, Palacios JM. Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res 1993; 18: 187-92
30. 30. Meador-Woodruff JH, Grandy DK, Van Tol HH, et al. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 1994; 10: 239-48
31. 31. Meador-Woodruff JH, Damask SP, Wang J, et al. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 1996; 15: 17-29
32. 32. Valerio A, Belloni M, Gorno ML, et al. Dopamine D2, D3, and D4 receptor mRNA levels in rat brain and pituitary during aging. Neurobiol Aging 1994; 15: 713-9
33. 33. Barili P, Bronzetti E, Felici L, et al. Age-dependent changes in the expression of dopamine receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 1996; 71: 45-50
34. 34. Hurley MJ, Stubbs CM, Jenner P, et al. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 1996; 214: 75-8
35. 35. Nagai Y, Ueno S, Saeki Y, et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996; 46: 791-5
36. 36. Ryoo HL, Pierottie D, Joyce JN. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's Disease, Mov Disord 1998; 13: 788-97
37. 37. Bordet R, Ridray S, Carboni S, et al. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci U S A 1997; 94: 3363-7
38. 38. Schwartz JC, Diaz J, Bordet R, et al. Functional implications of multiple dopamine receptor subtypes; the D1/D3 receptor co-existence. Brain Res Brain Res Rev 1998; 26: 236-42
39. 39. Mierau J, Schingnitz G. Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist. Eur J Pharmacol 1992; 215: 161-70
40. 3 dopamine receptor, in rat brain: a receptor binding and qualitative autoradiographic study. Neuropsychopharmacology 1998; 18 (4): 305-16
41. 41. Levesque D, Martres MP, Diaz J, et al. A paradoxical regulation of the dopaminc D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc Natl Acad Sci U S A 1995; 92: 1719-23
42. 42. Mierau J, Bechtel WD. SND 919 inhibits dopamine release in vivo and in vitro [abstract]. Psychopharmacology 1988; 96: 338
43. 43. Svensson K, Carlsson A, Huff RM, et al. Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol 1994; 263: 235-43
44. 44. O'Hara CM, Uhland-Smith A, O'Malley KL, et al. Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol ExpTher 1996; 277: 186-92
45. 45. Aretha CW, Sinha A, Galloway MP. Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther 1995; 274: 609-13
46. 46. Gainetdinov RR, Sotnikova TD, Grekhova TV, et al. In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol 1996; 308: 261-9
47. 47. Gobert A, Rivet JM, Audinot V, et al. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and 'silent' D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther 1995; 275: 899-913
48. 48. Pugsley TA, Davis MD, Akunne HC, et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128,907. J Pharmacol Exp Ther 1995; 275: 1355-66
49. 49. Tang L, Todd RD, O'Malley KL. Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther 1994; 270: 475-9
50. 50. Damsma G, Bottema T, Westerink BH, et al. Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol 1993; 249: R9-10
51. 51. Gilbert DB, Cooper SJ. 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects? Pharmacol Biochem Behav 1995; 52: 275-80
52. 52. Patel J, Trout SJ, Palij P. et al. Biphasic inhibition of stimulated endogenous dopamine release by 7-OH-DPAT in slices of rat nucleus accumbens. Br J Pharmacol 1995; 115: 421-6
53. 53. Yamada S, Yokoo H, Nishi S. Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res 1994; 648: 176-9
54. 54. Bowery B, Rothwell LA, Scabrook GR. Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral legmental area. Br J Pharmacol 1994; 112: 873-80
55. 55. Devoto P, Collu M, Muntoni AL, et al. Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse 1995; 20: 153-5
56. 56. Kreiss DS, Bergstrom DA, Gonzalez AM, et al. Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol 1995; 277: 209-14
57. 57. Diaz J, Levesque D, Lammers CH, et al. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 1995; 65: 731-45
58. 58. Le Moine C, Bloch B, D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J Comp Neurol 1995; 355: 418-26
59. 59. Le Moine C, Bloch B. Expression of the D3 dopamine receptor in peptidergic neurons of the nucleus accumbens: comparison with the D1 and D2 dopamine receptors. Neuroscience 1996; 73: 131-43
60. 2 receptor. Clin Neuropharmacol 1995, 18 Suppl.: S130-S142
61. 3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. J Neuroscience 1997; 17: 2519-30
62. 62. Ahlenius S, Salmi P. Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 1994; 260: 177-81
63. 63. Daly SA, Waddington JI., Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other 'D-2-like' agonists. Neuropharmacology 1993; 32: 509-10
64. 64. Sautel F, Griffon N, Levesque D, et al. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 1995; 6: 329-32
65. 65. Waters N, Svensson K, Haadsma-Svensson SR, et al. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity [see comments). J Neural Transm Gen Sect 1993; 94: 11-9
66. 66. Accili D, Fishburn CS, Drago J, et al. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc Natl Acad Sci U S A 1996; 93: 1945-9
67. 67. Caine SB, Koob GF. Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science 1993; 260: 1814-6
68. 68. Chaperon F, Thiebot MH. Effects of dopaminergic D3 receptor preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol 1996; 7: 105-9
69. 69. Depoorterc R, Perrault G, Sanger DJ. Behavioral effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl) 1996; 124: 231-40
70. 70. Kling-Petersen T, Ljung E, Svensson K. The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm. Pharmacol Biochem Behav 1994; 49: 345-51
71. 71. Sanger DJ, Depoortere R, Perrault G. Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behavior in rats. Behav Pharmacol 1996;7:477-82
72. 72. Lamas X, Negus SS, Nader MA, et al. Effects of the putative dopamine D3 receptor agonist 7-OH-DPAT in rhesus monkeys trained to discriminate cocaine from saline. Psychopharmacology (Berl) 1996; 124: 306-14
73. 73. Maj J, Rogoz Z, Skuza G, et al. Antidepressant effects of pramipexole, a novel dopamine rcceplor agonist. J Neural Transm 1997; 104: 525-33
74. 74. Willner P, Lappas S, Checta S, et al. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology (Berl) 1994; 115: 454-62
75. 75. Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 1998; 21 (3): 169-75
76. 76. Frucht SJ, Rogers J, Greene PE, et al. Falling asleep at the wheel: a serious side effect of pramipexole and ropinirole [abstract]. Neurology 1999; 52 Suppl. 2: A409
77. 77. Lagos P, Scorza C, Moti JM, et al. Effects of the D3 preferring dopamine agonist pramipexole on sleep and waking, locomotor activity and striatal dopamine release in rats. Eur Neuropsychopharmacol 1998; 8: 113-20
78. 78. Opacka-Juffry J, Ashworth S, Hume SP, et al. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Neuroreport 1995; 7: 348-52
79. 3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21: 141-51
80. 80. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992; 32 Suppl.: S2-9
81. 81. Graham DG, Tiffany SM, Bell WRJ, et al. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644-53
82. 82. Michel PP, Hefti F, Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 26: 428-35
83. 83. Steece-Collier K, Collier TJ, Sladek CD, et al. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990; 110: 201-8
84. 84. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992; 7: 23-31
85. 85. Ling ZD, Pieri SC, Carvey PM. Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons. Clin Neuropharmacol 1996; 19: 360-5
86. 86. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381-9
87. 87. Di Monte DA, Chan P, Sandy MS. Glutathione in Parkinson's disease: a link between oxidative stress and mitochondrial damage? Ann Neurol 1992; 32 Suppl.: S111-5
88. 88. Olanow CWI, Lieberman A. Scientific basis for the treatment of Parkinson's Disease. New Jersey: Parthenon Publishing Group. Inc., 1992
89. 89. Ling ZD, Pieri S, Carvey PM. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm 1997; 104: 209-28
90. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J Pharm Exp Ther 1999; 289: 202-10
91. 91. Ling ZD, Tong CW, Carvey PM. Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures. Brain Res 1998; 791: 137-45
92. 92. Zou LL, Rowe DB, Xie WJ, et al. Pramipexole protects dopaminergic cell line mes 23.5 against dopamine and levodopa induced cytotoxicity [abstract]. Soc Neurosci Abstr 1997; 23 (I): 272
93. 93. Cassarino DS, Fall CP, Smith TS, et al. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the Parkinsonian Neurotoxin methylpyridinium ion. J Neurochem 1998; 71: 295-301
94. 94. Herrera-Marschitz M, Luthman J, Ferre S. Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: II. Effects on extracellular monoamine, acetylcholine and adenosine levels monitored with in vivo microdialysis. Psychopharmacology (Berl) 1994; 116: 451-6
95. 95. Sethy VH, Wu H, Oostveen J, et al. Neuroprotective effects of dopamine agonists pramipexole and bromocriptine in 3 acetylpyridine-treated rats. Brain Res 1997; 754: 181-6
96. 96. Kitamura Y, Kohne Y, Nakaazawa M, et al. Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6n mice. Jpn J Pharmacol 1997; 74: 51-7
97. 97. Gassen M, Glinka Y, Pinchasi B, et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial traction. Eur J Pharmacol 1996; 308: 219-25
98. 98. Gassen M, Pinchasi B, Youdim MB. Apomorphine is a potent radical scavengaer and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induccd cell death. Adv Pharmacol 1998; 42: 320-4
99. 99. Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem 1996; 67: 2208-11
100. 100. Ogawa N, Tanaka K, Asanuma M, et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 1994; 657: 207-13
101. 101. Sawada H, Ihi M, Kihara T, et al. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol 1998; 44: 110-9